The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.
The FDA’s latest approval of the nasal spray Spravato (esketamine ... Ketamine molecules contain two parts: S-ketamine (esketamine), which is like the left hand, and R-ketamine, which is ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...
Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback